Minerva Neurosciences (NERV) Accounts Payables (2013 - 2026)

Minerva Neurosciences has reported Accounts Payables for 14 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 231.0% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (up 231.0% YoY), and the FY2025 full-year result was $1.7 million, up 2.67% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.1 million, up from $1.7 million in the prior quarter.
• The five-year high for Accounts Payables was $3.4 million in Q2 2024, with the low at $407909.0 in Q4 2022.
• Historically, Accounts Payables has averaged $1.5 million across 5 years, with a median of $1.6 million in 2024.
• Annual changes were most pronounced in 2022 — Accounts Payables sank 77.99% — and 2023, when it surged 276.33%.
• Minerva Neurosciences' Accounts Payables stood at $407909.0 in 2022, then surged by 276.33% to $1.5 million in 2023, then grew by 4.74% to $1.6 million in 2024, then increased by 2.67% to $1.7 million in 2025, then grew by 28.32% to $2.1 million in 2026.
• The last three Accounts Payables figures came in at $2.1 million (Q1 2026), $1.7 million (Q4 2025), and $944492.0 (Q3 2025), per Business Quant data.